Table of Contents

Type 2 diabetes and obesity are two of the most pressing health challenges worldwide, often going hand in hand and amplifying the risk of severe complications such as heart disease and stroke. While diet and exercise remain essential, they are often insufficient on their own.

That’s where breakthrough medications like semaglutide and tirzepatide come in, offering innovative solutions to these complex problems. In this article, we’ll explore how these treatments work, their benefits, and their differences to help you better understand their potential impact.

What is the Difference Between Semaglutide and Tirzepatide?

Parameters Semaglutide Tirzepatide
Brand Names Rybelsus, Ozempic, and Wegovy Zepbound and Mounjaro
Cost $968.52 to $1,349.02/package $1,059.87 to $1,069.08/per package
Approved Indications Chronic weight management for overweight or obese individuals aged 12 years and older,  glycemic control in adults with type 2 diabetes, and risk reduction of MACE in adults with established cardiovascular disease. Chronic weight management for overweight or obese adults and glycemic control in adults with type 2 diabetes.
Route of Administration Subcutaneous injection and oral Subcutaneous injection
Available Dosage Forms Prefilled pen and oral tablet Single-dose pen and vial
Available Dosage Strengths 3 mg, 7 mg, and 14 mg for the tablets and 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.0 mg, and 2.4 mg for the pens 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg for the pens and vials
Dosage Frequency Once a week (pen) and once daily (tablet) Once a week
Initial Dose 3 mg for the tablets and 0.25 mg for the pens 2.5 mg
Maximum Recommended Dose 14 mg for the tablets, 2.0 mg for the pens (diabetes), or 2.4 mg (weight loss) 15 mg
Side Effects Nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis. Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease.

Semaglutide vs Tirzepatide Mechanism of Action

Tirzepatide is a dual agonist, meaning it works on two key receptors in the body–GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

The GLP-1 receptor activation helps increase insulin secretion, reduce glucagon (a hormone that raises blood sugar), slow down how quickly food leaves the stomach, and even suppress appetite. On top of that, GIP receptor activation boosts insulin release further and improves fat metabolism and appetite control. This dual action makes tirzepatide highly effective for lowering blood sugar levels and promoting significant weight loss.

Tirzepatide is marketed under two brand names, Mounjaro and Zepbound. Each is approved for specific purposes:

    • Mounjaro: Primarily prescribed to improve blood sugar control in adults with type 2 diabetes, used alongside diet and exercise.
    • Zepbound: Targeted at adults with obesity or overweight conditions as an adjunct to a calorie-reduced diet and increased physical activity.

On the other hand, semaglutide, marketed as Ozempic, Wegovy, or Rybelsus, focuses solely on activating the GLP-1 receptor. It provides similar benefits, such as increased insulin secretion, decreased glucagon, slower gastric emptying, and appetite suppression. However, because semaglutide doesn’t target GIP receptors, its effects are limited to what the GLP-1 pathway can achieve.

Each semaglutide brand is also approved for a specific purpose:

    • Ozempic: A once-weekly injection approved for type 2 diabetes.
    • Wegovy: Also a once-weekly injection but specifically approved for weight loss.
    • Rybelsus: The oral version of semaglutide, taken daily and approved for type 2 diabetes.

Semaglutide vs Tirzepatide For Weight Loss

The clinical trial, known as SURMOUNT-5, compared these two medications (Zepbound vs Wegovy) in adults living with obesity without diabetes.

On average, people taking tirzepatide lost 20.2% of their body weight—around 50 lbs for many participants. Meanwhile, those on semaglutide achieved an average loss of 13.7% or around 33 pounds.

Even more interesting, nearly 1 in 3 people on tirzepatide achieved at least a 25% reduction in body weight, compared to about 1 in 6 on semaglutide. This suggests tirzepatide may offer greater weight loss potential for many individuals.

In another study, researchers looked at data from real-world patients across various healthcare clinics in the US. Unlike participants in controlled clinical trials, these patients were simply receiving treatment as part of their regular care. The study specifically compared semaglutide and tirzepatide formulations labeled for treating type 2 diabetes (Mounjaro vs Ozempic) used either on-label or off-label.

The results were pretty striking–people taking tirzepatide were significantly more likely to achieve weight loss milestones compared to those on semaglutide:

    • 5% weight loss: 1.76 times more likely
    • 10% weight loss: 2.54 times more likely
    • 15% weight loss: 3.24 times more likely

What’s more, tirzepatide users started seeing bigger weight changes earlier and continued losing more weight over time. By 12 months, the difference between the two medications added up to a 6.9% greater weight loss in favor of tirzepatide.

Why Is This Important?

Real-world studies give a better sense of how medications work outside the idealized conditions of clinical trials. In trials, participants are closely monitored and must meet strict criteria, which may not reflect the diverse needs and behaviors of the general population.

This study helps show how tirzepatide and semaglutide perform in typical healthcare settings, offering insights into weight loss outcomes and side effects for real-world patients. It’s especially useful for healthcare providers who want to understand how these drugs might work for their patients beyond the clinical trial data.

Tirzepatide vs Semaglutide for Type 2 Diabetes

tirzepatide vs semaglutide for type 2 diabetes

The SURPASS-2 trial was designed to compare the effectiveness and safety of tirzepatide and semaglutide in managing type 2 diabetes. Results showed that all doses of tirzepatide outperformed semaglutide in reducing HbA1c levels, a key measure of blood sugar control over time.

Tirzepatide at 5 mg reduced HbA1c by 2.01% compared to 1.86% with semaglutide. Higher doses reduced HbA1c by 2.24% (10 mg) and 2.30% (15 mg).

Side Effects of Tirzepatide and Semaglutide

Both semaglutide and tirzepatide primarily cause gastrointestinal (GI) issues, as they act on GLP-1 receptors to slow gastric emptying and regulate appetite. Here’s a comparison based on their clinical use and trial data:
Side Effect Tirzepatide Semaglutide
Common Side Effects Mounjaro Zepbound Ozempic Wegovy Rybelsus
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Fatigue
Dyspepsia (indigestion)
Burping
Hair loss
Gastroesophageal reflux disease
Dizziness
Abdominal distension
Flatulence
Headache
Nasopharyngitis
Gastroenteritis
Serious Side Effects Mounjaro Zepbound Ozempic Wegovy Rybelsus
Acute pancreatitis
Risk of thyroid C-Cell tumors
Acute gallbladder disease
Hypoglycemia
Acute kidney injury
Hypersensitivity reactions
Suicidal behavior and ideation
Diabetic retinopathy complications
Severe gastrointestinal adverse reactions
Risk of pulmonary aspiration during general anesthesia
Increased heart rate

Dosage and Administration of Semaglutide & Tirzepatide

Here’s a breakdown of the differences in dosage and administration between semaglutide and tirzepatide:

Semaglutide Dosing Regimen

Ozempic:

    • Form: Subcutaneous injection (under the skin)
    • Dosage: Start with 0.25 mg once weekly for 4 weeks. Increase to 0.5 mg weekly. If needed, the dose can be escalated to 1 mg or a maximum of 2 mg weekly.
    • Administration: Inject once a week on the same day each week, with or without meals.

Wegovy:

    • Form: Subcutaneous injection
    • Dosage: Start with 0.25 mg once weekly and gradually increase the dose over 16 weeks to reach the maintenance dose of 2.4 mg weekly.
    • Administration: Similar to Ozempic—weekly injection, same day each week.

Rybelsus:

    • Form: Oral tablet
    • Dosage: Start with 3 mg daily for the first month, then increase to 7 mg daily. If needed, it can be escalated to 14 mg daily.
    • Administration: Take once daily on an empty stomach with no more than 4 ounces of water. Wait at least 30 minutes before eating or drinking anything else.

Tirzepatide Dosing Regimen

Mounjaro:

    • Form: Subcutaneous injection
    • Dosage: Start with 2.5 mg once weekly for the first 4 weeks. Increase to 5 mg weekly. Based on blood sugar control and tolerability, the dose may be gradually escalated to 7.5 mg, 10 mg, 12.5 mg, or 15 mg. Each dose level should be maintained for at least 4 weeks before increasing further.
    • Administration: Inject once weekly, on the same day each week, with or without meals.

Zepbound:

    • Form: Subcutaneous injection
    • Dosage: The dosing schedule is similar to Mounjaro, starting at 2.5 mg weekly and gradually increasing to a maximum of 15 mg weekly, depending on individual goals and tolerance.
    • Administration: Also given once a week, on the same day each week.

Expert Pick

Looking for a detailed guide on how to use these medications effectively? We’ve put together an article covering each drug’s dosing schedule.

Know when and how to adjust your dose safely!

Semaglutide vs Tirzepatide Cost Considerations

If cost-effectiveness is a priority, tirzepatide currently provides more value for weight loss than semaglutide. Here’s why:

    • Semaglutide: In the STEP 1 trial, semaglutide resulted in an average 12.4% weight reduction over 68 weeks. The estimated total cost for this duration is $22,878, or $1,845 per 1% body weight reduction.
    • Tirzepatide: In the SURMOUNT-1 trial, tirzepatide led to a 17.8% average weight reduction over 72 weeks. The estimated total cost for this period is $17,527, which is $985 per 1% reduction in body weight.

A separate study also concluded that tirzepatide is more cost-effective in achieving better blood sugar control. While tirzepatide appears to offer better value, its cost and accessibility can vary depending on:

    • Insurance Coverage: Being a newer medication, tirzepatide may not be covered by all insurance plans yet, especially for weight-loss-specific indications. Semaglutide is more established and might offer wider insurance acceptance.
    • Savings Programs, Discounts, and Coupons: Both tirzepatide and semaglutide brands offer ways to help patients reduce costs. For example, Eli Lilly (the manufacturer of tirzepatide) provides a savings program for eligible patients to reduce out-of-pocket expenses.

Exploring these savings options with a healthcare provider or pharmacist can make a significant difference in out-of-pocket costs.

Final Verdict: Semaglutide or Tirzepatide?

In comparing semaglutide and tirzepatide, several key distinctions emerge. Tirzepatide’s dual mechanism of action, targeting both GLP-1 and GIP receptors, results in enhanced blood sugar control and superior weight loss outcomes compared to semaglutide, which acts solely on GLP-1 receptors.

Clinical trials and real-world studies consistently demonstrate tirzepatide’s greater effectiveness in achieving significant weight loss and reducing HbA1c levels. However, semaglutide offers the convenience of both injectable and oral forms, making it a more flexible option for some patients.

Cost considerations and insurance coverage are also part of determining the right choice, with tirzepatide showing better cost-effectiveness for weight loss. In the end, the decision should be based on individual health needs, preferences, and financial factors in consultation with a healthcare provider.

Frequently Asked Questions

The main difference between them is their FDA-approved indications. Mounjaro is authorized for managing type 2 diabetes, whereas Zepbound is approved for long-term weight management in adults with obesity or excess weight. Both are administered as weekly subcutaneous injections and share similar dosing and side effects.

Switching from semaglutide to tirzepatide is not uncommon, especially for patients who may benefit from the dual action of tirzepatide. This switch might be considered if a patient is not achieving their desired outcomes with semaglutide. However, the decision should always be made under the guidance of a healthcare provider, considering the patient’s specific medical history and needs.

To determine if semaglutide is right for you, consult your primary physician, who will evaluate your medical history, current health status, and treatment goals. It may be a good option if you have not achieved adequate results with diet, exercise, or other medications. Your provider will also consider potential side effects, contraindications, and any interactions with other medications you are taking before recommending semaglutide.

For weight management, the FDA-approved doses for Zepbound (tirzepatide for weight loss) range from 2.5 mg to 15 mg, administered as a weekly injection. Your healthcare provider determines the exact dose based on your treatment response and tolerance.

Rybelsus (oral semaglutide) and Ozempic (injectable semaglutide) are both effective for managing type 2 diabetes. However, clinical studies suggest that Ozempic generally offers greater glycemic control and weight loss benefits than Rybelsus, likely due to its higher bioavailability through injection. However, Rybelsus may be preferred by patients who prefer oral medications over injections.

Tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not suitable for people with a history of severe hypersensitivity to the medication or any of its ingredients. Additionally, it should be used cautiously in individuals with a history of pancreatitis. Pregnant or breastfeeding individuals and those with certain gastrointestinal conditions should consult their healthcare provider to determine if tirzepatide is safe for them.

Liraglutide and semaglutide are both GLP-1 receptor agonists used to manage type 2 diabetes and aid in weight loss, but they differ in dosing, administration, and efficacy. Liraglutide requires daily injections, while semaglutide is administered weekly, offering greater convenience. Semaglutide has shown superior results in blood sugar control and weight loss compared to liraglutide in clinical studies. Additionally, semaglutide is available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) forms, whereas liraglutide is injectable only.

Once prescribed, you can purchase semaglutide at local pharmacies or through reputable online pharmacies. Some telehealth platforms offer online consultations and can facilitate prescriptions for semaglutide, which can then be filled at a pharmacy of your choice. For cost-saving options, online platforms like pharmacy partners in Canada, including Pharma Giant, offer semaglutide at potentially lower prices compared to US rates.

Combining semaglutide and tirzepatide is not a standard medical practice and lacks substantial clinical evidence to support its safety and efficacy.

Related Articles

Sources

Eli Lilly and Company. (2024). Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. Lilly Investors. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head

Rodriguez, P. J., Cartwright, B. M. G., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Internal Medicine, 184(9), 1056. https://doi.org/10.1001/jamainternmed.2024.2525

Frías, J. P., Davies, M. J., Rosenstock, J., Manghi, F. C. P., Landó, L. F., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021c). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/nejmoa2107519

Mody, R. R., Meyer, K. L., Ward, J. M., & O’Day, K. B. (2023). Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States. Diabetes Therapy, 14(12), 2045–2055. https://doi.org/10.1007/s13300-023-01470-w

Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2022). Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obesity and Metabolism, 25(4), 961–964. https://doi.org/10.1111/dom.14940

Eli Lilly and Company. (2024). Highlights Of Prescribing Information Of Mounjaro. Retrieved from https://pi.lilly.com/us/mounjaro-uspi.pdf?s=pi

Eli Lilly and Company. (2024). Highlights Of Prescribing Information Of Zepbound. Retrieved from https://pi.lilly.com/us/zepbound-uspi.pdf

Novo Nordisk. (2024). Highlights Of Prescribing Information Of Ozempic. Retrieved from https://www.novo-pi.com/ozempic.pdf

Novo Nordisk. (2024). Highlights Of Prescribing Information Of Wegovy. Retrieved from https://www.novo-pi.com/wegovy.pdf

Novo Nordisk. (2024). Highlights Of Prescribing Information Of Rybelsus. Retrieved from https://www.novo-pi.com/rybelsus.pdf